BLCO trades 18.5% below Wall Street's consensus target of $20.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BLCO achieves its forward estimates and maintains a stable P/E multiple of 21.5x. This scenario reflects the blended consensus of 17 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Bausch + Lomb Corporation (BLCO) has a Wall Street consensus price target of $20.20, based on estimates from 17 covering analysts. With the stock currently trading at $17.05, this represents a potential upside of +18.5%. The company has a market capitalization of $6.09B.
Analyst price targets range from a low of $16.00 to a high of $24.00, representing a 40% spread in expectations. The median target of $21.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, BLCO trades at a trailing P/E of -16.7x and forward P/E of 21.5x. Analysts expect EPS to grow +269.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HSICHenry Schein, Inc. | $9.7B | $85.05 | $92.33 | +8.6% | Buy | 15.8x | 34 |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 LNTHLantheus Holdings, Inc. | $6.5B | $99.97 | $104.48 | +4.5% | Buy | 18.5x | 19 |
 JNJJohnson & Johnson | $648.0B | $269.17 | $286.93 | +6.6% | Buy | 23.4x | 40 |
 ABTAbbott Laboratories | $180.3B | $103.53 | $121.50 | +17.4% | Buy | 18.8x | 41 |
 COOThe Cooper Companies, Inc. | $10.9B | $56.07 | $65.75 | +17.3% | Buy | 12.3x | 28 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 IARTIntegra LifeSciences Holdings Corporation | $1.2B | $15.53 | $20.50 | +32.0% | Buy | 6.3x | 26 |
 ALGNAlign Technology, Inc. | $10.6B | $148.17 | $205.25 | +38.5% | Buy | 13.1x | 33 |
 BHCBausch Health Companies Inc. | $2.1B | $5.71 | $9.83 | +72.2% | Buy | 1.2x | 38 |
Quick answers to the most common questions about buying BLCO stock.
Bausch + Lomb Corporation (BLCO) has a consensus 12-month price target of $20.2, implying 18.5% upside from $17.05. The 17 analysts covering BLCO see moderate appreciation potential.
BLCO has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is mixed, with 8 Hold ratings making up the largest segment. The consensus 12-month price target of $20.2 implies 18.5% upside from current levels.
BLCO trades at a forward P/E of 21.4763x, representing a moderate valuation. With analysts targeting $20.2 (18.5% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $24 for BLCO, while the most conservative target is $16. The consensus of $20.2 represents the median expectation. These targets typically reflect 12-month expectations.
BLCO is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 8 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BLCO stock forecast based on 17 Wall Street analysts shows a consensus price target of $20.2, with estimates ranging from $16 (bear case) to $24 (bull case). The median consensus rating is "Buy".
BLCO trades at a forward P/E ratio of 21.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on BLCO, with a "Buy" consensus rating and $20.2 price target (18.5% upside). 8 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BLCO analyst price targets range from $16 to $24, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20.2 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.